VISION IMPAIRMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

 Market Segmentation

• By Type (Revenue, USD Bn, 2021-2033)

  • Refractive Errors
  • Macular Degeneration
  • Retinitis Pigmentosa
  • Night Blindness
  • Others

• By Treatment (Revenue, USD Bn, 2021-2033)

  • Surgery
  • Devices
  • Medications
  • Others

• By Route of Administration (Revenue, USD Bn, 2021-2033)

  • Oral
  • Topical
  • Implant
  • Intravitreal
  • Others

• By

  End User (Revenue, USD Bn, 2021-2033)

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

• By Distribution Channel (Revenue, USD Bn, 2021-2033)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

•  By Region: (Revenue, USD Bn, 2021-2033)

  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

• Competitive Landscape

  • Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Bayer AG
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Regeneron Pharmaceuticals Inc.
  • Allergan
  • Neurotech, LLC
  • Gilead Sciences, Inc.
  • Adverum
  • STEMCELL Technologies Inc.
  • IVERIC bio
  • Kubota Pharmaceutical Holdings Co. Ltd.
  • Sanwa Kagaku Kenkyusho Co., Ltd
  • Opthea Limited
  • Santen Pharmaceutical Co., Ltd
  • PanOptica, Inc
  • Alcon
  • Phio Pharmaceuticals Corp
  • Bausch Health Companies Inc.